Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib

PURPOSE: To determine whether FDG PET can expand eligibility in biomarker-selected clinical trials by providing a means to quantitate response in patients with non-assessable disease by RECIST. EXPERIMENTAL DESIGN: SUMMIT (NCT01953926) is a multicenter phase II “basket” trial of the Pan-HER kinase i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Ulaner, Gary A., Saura, Cristina, Piha-Paul, Sarina A., Mayer, Ingrid, Quinn, David, Jhaveri, Komal, Stone, Ben, Shahin, Seta, Mann, Grace, Dujka, Melanie, Bryce, Richard, Meric-Bernstam, Funda, Solit, David B., Hyman, David M.
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7418635/
https://ncbi.nlm.nih.gov/pubmed/31548342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1658
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares